ArticleRenal failure2026
Urate-lowering therapy modifies associations between urinary urate and kidney outcome.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum uric acid is associated with chronic kidney disease (CKD) progression; however, causality remains uncertain. Although renal urate handling, rather than merely hyperuricemia, may dominate kidney outcomes, the prognostic value of urinary urate indices and the potential modifying effect of urate-lowering therapy (ULT) remain unclear.
methodsThis retrospective study included patients with an estimated glomerular filtration rate (eGFR) of 15-60 mL/min/1.73m
resultsAmong 551 patients (244 receiving ULT), 117 experienced MAKE over a median follow-up of 2.3 years. In the adjusted analysis, FEUA <5.5% was associated with a higher overall risk (hazard ratio [HR], 3.56; 95% CI, 1.96-6.48), with a stronger association in the no-ULT group (HR, 11.59; 95% CI, 3.80-35.31). Conversely, FEUA was not associated with the outcome within the ULT group. FEUA × ULT interaction was significant, indicating that the prognostic meaning of FEUA depends on concomitant ULT.C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.